0000000000725198

AUTHOR

Vincenzo Formica

showing 3 related works from this author

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin

2016

BACKGROUND: High Neutrophil/Lymphocyte ratio (NLR), as a measure of enhanced inflammatory response, has been negatively associated with prognosis in patients with localized pancreatic ductal adenocarcinoma (PDA). OBJECTIVE: In the present study, we aimed at investigating the prognostic value of NLR in two homogeneous groups of chemotherapy-na've metastatic PDA patients. Patients were treated with either gemcitabine (GEM) or gemcitabine/ oxaliplatin (GEMOXA). We also assessed whether NLR could identify patients benefiting from the use of oxaliplatin. METHODS: Consecutive PDA patients treated at the Medical Oncology Unit of Tor Vergata University Hospital of Rome with either GEM or GEMOXA wer…

Male0301 basic medicineOncologyCancer ResearchNeutrophil/lymphocyte ratio; gemcitabine; oxaliplatin; pancreatic ductal adenocarcinomaOrganoplatinum CompoundsNeutrophilsSettore MED/06 - Oncologia MedicaLymphocyteAntineoplastic AgentLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsLymphocytesNeoplasm MetastasisAged 80 and overNeutrophilPancreatic NeoplasmgemcitabineGeneral MedicineMiddle AgedPrognosisNeoplasm MetastasiTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioLymphocyteFemaleHumanCarcinoma Pancreatic Ductalmedicine.drugAdultmedicine.medical_specialtyPancreatic ductal adenocarcinomaPrognosiInflammatory responseeducationpancreatic ductal adenocarcinomaAntineoplastic Agents03 medical and health sciencesGeneticNegatively associatedInternal medicineMetastatic pancreatic cancerGeneticsmedicineHumansIn patientAgedProportional Hazards ModelsSettore MED/04 - Patologia GeneraleAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundfungioxaliplatinBiomarkerGemcitabineOxaliplatinPancreatic Neoplasms030104 developmental biologyROC CurveProportional Hazards ModelbusinessBiomarkers
researchProduct

Irinotecan or oxaliplatin: Which is the first move for the mate?

2020

Objectives: The aim of the present review is to discuss the potential link between RAS, BRAF and microsatellite instability (MSI) mutational patterns and chemotherapeutic agent efficacy [Irinotecan (IRI) vs. Oxaliplatin (OXA)], and how this can potentially influence the choice of the chemotherapy backbone. Methods: Following a review of the research literature, all pertinent articles published in the core journals were selected for the study. The inclusion criteria regarded relevant clinical and pre-clinical studies on the topic of interest (Relationship of OXA and IRI to KRAS/BRAF mutations and MSI). Results: Excision repair cross complementation group 1 (ERCC1) expression is inhibited by…

Proto-Oncogene Proteins B-rafColorectal cancerPopulationmedicine.disease_causeIrinotecanBiochemistryDNA Mismatch RepairSettore MED/06BRAFDrug DiscoveryKRASMedicineChemotherapyHumanseducationMSIPharmacologyeducation.field_of_studybusiness.industryOrganic ChemistryMicrosatellite instabilitymedicine.diseaseColorectal cancerdigestive system diseasesOxaliplatinIrinotecanOxaliplatinGenes rasMutationCancer researchMolecular MedicineMolecular targetsDNA mismatch repairMicrosatellite InstabilityKRASERCC1businessColorectal Neoplasmsmedicine.drug
researchProduct

TNF-alpha gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy

2013

Abstract Background TNF-α has been proposed as a predictive factor for venous thromboembolism (VTE). Genetic polymorphisms could regulate TNF-α production. However, the relationship between TNFA gene variants and VTE is not clarified. This study aims to investigate the predictive role of five different TNFA gene promoter SNPs, or their haplotype combination(s), for a first VTE episode in gastrointestinal cancer out-patients treated with chemotherapy. Patients and methods Serum TNF-α levels and TNFA -863C/A, -857C/T, -376G/A, -308G/A and -238G/A gene promoter polymorphisms were retrospectively evaluated in 314 subjects, including 157 controls and 157 Caucasian patients with histologically di…

MaleAntimetabolitesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentchemotherapyGastroenterologysingle nucleotide polymorphismschemotherapy; gastrointestinal cancer; single nucleotide polymorphisms; tumour necrosis factor-α; venous thromboembolismsingle nucleotide polymorphismPhytogenic80 and overtumour necrosis factor-αPromoter Regions GeneticGastrointestinal NeoplasmsAged 80 and overHazard ratioSingle NucleotideHematologyMiddle AgedAntineoplasticChemotherapy regimenOncologyFemaleFluorouracilmedicine.drugAdultRiskAntimetabolites Antineoplasticmedicine.medical_specialtygastrointestinal cancervenous thromboembolismAntineoplastic AgentsSingle-nucleotide polymorphismIrinotecanPolymorphism Single NucleotidePromoter RegionsGeneticInternal medicinemedicineHumansGenetic Predisposition to DiseaseGastrointestinal cancercardiovascular diseasesPolymorphismRetrospective StudiesAgedChemotherapyTumor Necrosis Factor-alphabusiness.industryHaplotypeOdds ratiomedicine.diseaseAntineoplastic Agents PhytogenicIrinotecanHaplotypesCase-Control StudiesImmunologyCamptothecinHuman medicinePolymorphism Single Nucleotide; Antimetabolites Antineoplastic; single nucleotide polymorphisms; Humans; Retrospective Studies; Aged; Promoter Regions Genetic; Haplotypes; Aged 80 and over; Adult; gastrointestinal cancer; Genetic Predisposition to Disease; Male; tumour necrosis factor-α; Tumor Necrosis Factor-alpha; Venous Thromboembolism; Camptothecin; chemotherapy; Risk; Fluorouracil; Case-Control Studies; Gastrointestinal Neoplasms; Middle Aged; venous thromboembolism; Antineoplastic Agents Phytogenic; Femalebusiness
researchProduct